Author + information
- Michael Miller,
- Christie Ballantyne,
- Harold Bays,
- Craig Granowitz,
- Ralph Doyle,
- Rebecca Juliano and
- Sephy Philip
Elevated hsCRP is associated with increased CV risk. Icosapent ethyl is high-purity prescription eicosapentaenoic acid approved at 4 g/day as an adjunct to diet to reduce triglycerides (TGs) in adults with TG ≥500 mg/dL.
The 12-week ANCHOR study randomized 702 statin-treated patients at increased CV risk with TGs 200-499 mg/dL despite LDL-C control (40-99 mg/dL). This post-hoc analysis assessed 246 ANCHOR patients with baseline hsCRP ≥2.0 mg/L (55% male, 98% white, 75% with diabetes; mean age, 61 years) randomized to icosapent ethyl 4 g/day (n=126) or placebo (n=120). Analyses included median percent change from baseline to week 12 vs placebo in lipids, lipoproteins, and inflammatory markers.
Icosapent ethyl significantly reduced TGs (–20%; P<0.0001) without increasing LDL-C vs placebo. Other atherogenic and inflammatory parameters also significantly improved vs placebo (Figure). Eicosapentaenoic acid levels increased 637% in plasma and 632% in red blood cells vs placebo (both P<0.0001). Icosapent ethyl exhibited a safety profile similar to placebo.
In statin-treated patients with TGs 200-499 mg/dL and hsCRP ≥2.0 mg/L, icosapent ethyl 4 g/day safely and significantly reduced TGs and other atherogenic and inflammatory parameters without increasing LDL-C vs placebo. The REDUCE-IT trial is evaluating the potential benefit of icosapent ethyl on CV outcomes in statin-treated patients with high CV risk, including some patients with hsCRP ≥2.0 mg/L.
Poster Hall, Hall A/B
Monday, March 12, 2018, 9:45 a.m.-10:30 a.m.
Session Title: Pharmacologic and Non-Pharmacologic Updates in Cardiovascular Disease
Abstract Category: 15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 1287-251
- 2018 American College of Cardiology Foundation